Key Information
Source
summary/abstract
New data shows that long-term treatment with acoramidis is associated with lower mortality and fewer hospitalizations in people with transthyretin amyloid cardiomyopathy (ATTR-CM)external link, opens in a new tab, according to a studyexternal link, opens in a new tab published in JAMA Cardiology.
In an extension of the ATTRibute-CM clinical trial, researchers followed 389 participants for up to 54 months. Patients who received acoramidis for the entire study period had a 45% lower risk of death overall and a 49% lower risk of death due to heart disease compared with those who started the study on a placebo and switched to acoramidis later on. They also had a 47% lower risk of cardiovascular hospitalization.